Bempedoic Acid Pregnancy Surveillance Program
← catalyst calendarNCT05103254 · readout ≤ 2,112 d
Sponsored by Esperion Therapeutics, Inc. (industry) · ESPR — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
20estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-09-01 | actual | When the study began enrolling |
| Primary completion | May 2032 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | May 2032 | estimated | The whole study's end, after follow-up |
| First posted | 2021-11-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-05-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Pregnancy
- Hyperlipidemias
Interventions
- Drug: Bempedoic Acid — also filed as Nexletol
- Drug: Bempedoic Acid / Ezetimibe — also filed as Nexlizet
Primary outcome
what the primary-completion date above is the date OFMajor congenital malformations (MCM)
measured Birth up to 12 months
Publications
- PMID 38085172 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · ESPR's whole pipeline · Catalyst calendar · Every registered study · What changed